The research aims to improve the surgical treatment results of incisional ventral hernia by applying a case-specific approach and a new method of anterior abdominal wall surgery. The paper reports the results of the prospective dynamic cohort study on 219 patients under 60 years of age, with small and medium hernias and up to 10 cm defects in the anterior abdominal wall (W1-W2), who underwent incisional ventral hernia treatment with mesh endoprostheses. The paper offers a selection algorithm for anterior abdominal wall repair surgery and an original proprietary technique. We have developed and described in detail a new 'extra-sublay' technique of surgical intervention. The paper displays the frequency and pattern of complications, as well as the quality of life of patients after different prosthetic surgeries. In the main group, 65.0% of patients showed improvement, 88.4% showed long-term surgical success, 13.6% faced complications, and 4.5% experienced recurrence. After receiving the "on lay" treatment, 59.4% of patients showed positive results, 74.7% showed long-term surgical success, 40% had complications, and 3.1% experienced recurrence. After the "sub lay" intervention, 40.0% of patients demonstrated excellent results, 81.9% reached long-term success, 12% had complications, and 1.4% encountered recurrence. The article shows a selection algorithm for anterior abdominal wall plastic repair method.One of the factors that cause relapses and ventral hernias themselves is obesity.The authors' method of the VH surgical treatment has shown good results.Excellent indicators showed 65.0% of patients of the main group. The article shows a selection algorithm for anterior abdominal wall plastic repair method.One of the factors that cause relapses and ventral hernias themselves is obesity.The authors' method of the VH surgical treatment has shown good results.Excellent indicators showed 65.0% of patients of the main group.The global pandemic emergent from SARS-COV-2 (COVID-19) has continued to cause both health and socio-economic challenges worldwide. https://www.selleckchem.com/products/bay-61-3606.html However, there is limited information on the factors affecting the dynamics of COVID-19, especially in developing countries, including African countries. In this study, we have focused on understanding the association of COVID-19 cases with environmental and socioeconomic factors in Zambia - a sub-Saharan African country. We used Zambia's district-level COVID-19 data, covering 18 March 2020 (i.e., from first reported cases) to 17 July 2020. Geospatial approaches were used to organize, extract and establish the dataset, while a classification tree (CT) technique was employed to analyze the factors associated with the COVID-19 cases. The analyses were conducted in two stages (1) the binary analysis of occurrences of COVID-19 (i.e., COVID-19 or No COVID-19), and (2) a risk level analysis which grouped the number of cases into four risk levels (high, moderate, low and very low). The tionship between COVID-19 cases and their associated environmental and socioeconomic factors. Further studies are needed to understand the relationship of this disease and the associated factors in different cultural settings, seasons and age groups, especially as the COVID-19 cases increase and spread in many countries.The imposition and lifting of non-pharmaceutical interventions (NPIs) to avert the COVID-19 pandemic have gained popularity worldwide and will continue to be enforced until herd immunity is achieved. We developed a linear regression model to ascertain the nexus between the time-varying reproduction number averaged over a time window of six days (Rts) and seven NPIs contact tracing, quarantine efforts, social distancing and health checks, hand hygiene, wearing of facemasks, lockdown and isolation, and health-related supports. Our analysis suggests that the second wave that emerged in Sri Lanka in early October 2020 continued despite numerous NPIs. The model indicates that the most effective single NPI was lockdown and isolation. Conversely, the least effective individual NPIs were hand hygiene and wearing of facemasks. The model also demonstrates that to mitigate the second wave to a satisfactory level (Rts less then 1), the best single NPI was the contact tracing with stringent imposition (% of improvement of Rts was 69.43 against the base case). By contrast, the best combination of two NPIs was the lockdown & isolation with health-related supports (% of improvement was 31.92 against the base case). As such, many health authorities worldwide can use this model to successfully strategize the imposition and lifting of NPIs for averting the COVID-19 pandemic. The effects of the coronavirus disease 19 (COVID-19) pandemic in particular affect those with chronic kidney disease (CKD), who commonly have defects in humoral and cellular immunity, and the efficacy of vaccinations against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is uncertain. To inform public health and clinical practice, we synthesized published studies and preprints evaluating surrogate measures of immunity after SARS-CoV-2 vaccination in patients with CKD including those receiving dialysis or with a kidney transplant. We found 35 studies (28 published, 7 preprints), sample size from 23 to 1140 patients, and follow-up from one week to 1 month after vaccination. 17 of the 35 studies enrolled a control group. In the 22 studies of patients receiving dialysis, the development of antibodies was observed in 18 to 53% after one dose, and in 70 to 96% after two doses of mRNA vaccine. In the 14 studies of transplant recipients, 3% to 59% mounted detectable humoral or cellular responses ashould be considered. As additional data arise, the NephJC COVID-19 page will be updated (http//www.nephjc.com/news/covid-vaccine). Remdesivir has demonstrated antiviral activity against coronavirus, shortening the time to recovery in adults hospitalized with moderate/severe COVID-19. Severe adverse events such as acute kidney injury (AKI) have been reported. There is little available data on the use and safety of remdesivir in kidney transplant (KT) recipients. We present a multicenter cohort study of 51 KT recipients with COVID-19 treated with remdesivir. Outcomes and safety were assessed. Mean age at diagnosis was 60 years, with a median time since KT of 4.5 years. Mean time since admission to remdesivir was 2 days. Twenty-eight patients (54.9%) required mechanical ventilation (19 non-invasive). Mortality was 18.9%, markedly higher if ≥65 years-old (45% vs. 3.2% in younger patients). AKI was present in 27.7% of patients, but in 50% of cases it was diagnosed before treatment. Remdesivir did not require discontinuation because of adverse events in any case. We did not find significant hepatoxicity or systemic symptoms resultant from the drug.